Hassabis on AI for Drug Discovery
Chris_Armstrong · x · 2026-07-13
Demis Hassabis believes one of the most vital applications of AI is helping cure a massive number of diseases.
He emphasizes that Isomorphic Labs isn't about building chatbots, but rather accelerating the entire drug discovery pipeline: making the path from predicting molecular properties to clinical trials faster and more efficient. Because models can better predict the properties of candidate drugs, they are more likely to pass these trials. Hassabis notes this capability offers enormous social value and could spawn a "hundreds of billions of dollars" commercial opportunity.
The core takeaway: the true value of AI in health lies not in another chatbot assistant, but in compressing drug discovery cycles and translating that speed into commercial returns.
More from Research
- π0.5 study: raising demos from 10 to 438 lifts Place Ball in Bowl success from 7% to 83% — stingning · 2026-10-27
- HandsOn benchmark: 66 verified tasks and 18,000 human demos for dexterous manipulation — stingning · 2026-10-27
- HandsOn benchmark: 66 human-verified tasks and 18,000 curated demos for dexterous manipulation — stingning · 2026-10-27
- HandsOn splits evaluation: Core-50 execution vs Transfer-16 zero-demo transfer — stingning · 2026-10-27
- Best policy hits only 29.1% on HandsOn; tool use drops to 2.9%, transfer near zero — stingning · 2026-10-27
- FrontierCS 2 launches on Kaggle: 48 tasks make agents beat published CS papers — MeganRisdal · 2026-10-27